These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25830192)

  • 1. Benefits, risks of SGLT2 inhibitors explored at session.
    Caffrey MK
    Am J Manag Care; 2014 Jul; 20(10 Spec No):E11. PubMed ID: 25830192
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 inhibitors in the treatment of type 2 diabetes.
    Hasan FM; Alsahli M; Gerich JE
    Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding J
    Lancet Diabetes Endocrinol; 2016 May; 4(5):379-81. PubMed ID: 27009624
    [No Abstract]   [Full Text] [Related]  

  • 4. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors: the latest "new kids on the block"!
    Cefalu WT; Riddle MC
    Diabetes Care; 2015 Mar; 38(3):352-4. PubMed ID: 25715412
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
    Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
    Ribola FA; Cançado FB; Schoueri JH; De Toni VF; Medeiros VH; Feder D
    Eur Rev Med Pharmacol Sci; 2017 Jan; 21(1):199-211. PubMed ID: 28121337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus].
    Dagan A; Dagan B; SegaL G
    Harefuah; 2015 Mar; 154(3):200-3, 210. PubMed ID: 25962253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose transporter 2 inhibitors in type 2 diabetes mellitus: navigating between Scylla and Charybdis.
    Machado UF; Corrêa-Giannella ML
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):5-9. PubMed ID: 24397354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
    Cai X; Yang W; Gao X; Chen Y; Zhou L; Zhang S; Han X; Ji L
    Obesity (Silver Spring); 2018 Jan; 26(1):70-80. PubMed ID: 29165885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison chart of SGLT2 inhibitors.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):e26. PubMed ID: 28118654
    [No Abstract]   [Full Text] [Related]  

  • 14. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
    Deshmukh AB; Patel MC; Mishra B
    Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
    Rajeev SP; Cuthbertson DJ; Wilding JP
    Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
    Avogaro A; Delgado E; Lingvay I
    Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.
    Tamura K; Wakui H; Azushima K; Uneda K; Umemura S
    Hypertens Res; 2016 Jun; 39(6):396-8. PubMed ID: 26818654
    [No Abstract]   [Full Text] [Related]  

  • 20. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.